Skip to main content
Health & Medicine

Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.

| Source: Lancet (London, England)

Efinopegdutide is a pharmacologically distinct once-weekly GLP-1-glucagon receptor co-agonist with a relative receptor potency balance of approximately 2:1 under development for metabolic dysfunction-associated steatohepatitis (MASH). We aimed to investigate the efficacy and safety of efinopegdutide in adults with non-cirrhotic MASH. We did a phase 2b, randomised, placebo-controlled, double-blind study conducted at 176 academic and community centres in 26 countries. We included adults (aged &#x2

Efinopegdutide is a pharmacologically distinct once-weekly GLP-1-glucagon receptor co-agonist with a relative receptor potency balance of approximately 2:1 under development for metabolic dysfunction-associated steatohepatitis (MASH). We aimed to investigate the efficacy and safety of efinopegdutide in adults with non-cirrhotic MASH. We did a phase 2b, randomised, placebo-controlled, double-blind study conducted at 176 academic and community centres in 26 countries. We included adults (aged ≥18 years) with biopsy-confirmed MASH and stage 2 or stage 3 fibrosis. Eligible participants were randomly assigned (1:1:1:1:1) to receive either efinopegdutide (4 mg, 7 mg, or 10 mg), placebo, or open-label semaglutide 2·4 mg, all administered subcutaneously once weekly. Randomisation was performed centrally. The primary endpoint was MASH resolution without worsening of fibrosis at week 52. The key secondary histological endpoint was fibrosis improvement of at least one stage without worsening of steatohepatitis. Missing end-of-treatment biopsies were considered as failure for the primary analysis. This study is registered with EU CT, 2022-502647-35-00, and ClinicalTrials.gov, NCT05877547, and is complete. Between June 23, 2023, and Dec 29, 2025, we screened 1704 participants. We randomly assigned 386 (23%) participants, of whom 381 (99%; 194 [51%] women and 187 [49%] men) received at least one dose of study intervention and were included in the analysis. Baseline characteristics were similar across groups; 239 (63%) of 381 participants had F2 fibrosis and 142 (37%) had F3 fibrosis; the mean age of participants was 53 years (SD 13). At week 52, MASH resolution without worsening of fibrosis occurred in 31 (56%) of 55 participants in the 4 mg efinopegdutide group, 31 (63%) of 49 participants in the 7 mg efinopegdutide group, and 35 (61%) of 57 participants in the 10 mg efinopegdutide group versus seven (13%) of 53 participants in the placebo group (difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg); 26 (53%) of 49 participants receiving semaglutide met this endpoint. For the key secondary endpoint, fibrosis improvement of at least one stage without worsening of steatohepatitis occurred in 32 (43%) of 75 participants in the efinopegdutide 4 mg group, 39 (52%) of 75 participants in the 7 mg efinopegdutide group, and 26 (34%) of 77 participants in the efinopegdutide 10 mg group versus 16 (21%) of 77 participants receiving placebo (difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group); 16 (25%) of 65 participants receiving semaglutide met this endpoint. The most frequently reported adverse events with efinopegdutide were gastrointestinal, with the highest rates among participants receiving efinopegdutide 10 mg. Adverse events leading to discontinuation of study intervention occurred more frequently among participants receiving efinopegdutide 10 mg (nine [11%] of 79 participants) compared with the other doses of efinopegdutide (range 3-4%) or placebo (one [1%]). Treatment with efinopegdutide resulted in a significantly greater proportion of participants with MASH resolution without worsening of fibrosis compared with placebo. The 7 mg dose showed the most favourable benefit-risk profile, improving fibrosis by at least one stage without worsening steatohepatitis in approximately half of participants after 1 year of treatment. These findings support the potential utility of efinopegdutide as a once-weekly GLP-1-glucagon receptor co-agonist in MASH. Merck Sharp & Dohme, a subsidiary of Merck & Co.

Read the original source →

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading